Fluidic Analytics: Fluidic Analytics Fluidity One-W for antibody affinity and concentration in undiluted serum

The emergence of mutant variants of SARS-CoV-2 and associated concerns about the effects of these mutations on the efficacy of vaccines and therapeutics has underscored the vital importance of understanding the antibody response to SARS-CoV-2. Using the Fluidity One-W, measurements to determine the affinity, concentration and neutralisation potential of antibodies can be performed directly in human serum. In the recent paper 'In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum' the capabilities of the Fluidity One-W serum platform were shown. The product offers an in-solution, receptor-binding competition assay that quantifies the affinity, concentration and neutralisation potential of antibodies against the SARS-CoV-2 spike protein. The platform has the ability to quantitatively profile the underlying protein interactions directly in serum. Scientists who would like to book a trial, to see how the capabilities of the Fluidity One-W serum can support their research, can do so by contacting ATA Scientific. For more information: https://www.fluidic.com/resources/antibody-affinity-governs-inhibition-of-SARS-CoV-2/.